摘要
乳腺癌干细胞(breast cancer stem cells,BCSCs)是存在于乳腺癌组织中的数量很少、具有自我更新能力和产生异质性肿瘤细胞的细胞亚群。内分泌耐药是目前内分泌治疗应用的主要限制。现有研究表明,BCSCs在乳腺癌内分泌治疗耐药中发挥重要作用。本文就BCSCs在激素受体(hormone receptor,HR)阳性乳腺癌内分泌治疗耐药中的作用进行综述。
Breast cancer stem cells(BCSCs)represent a small subpopulation of tumor cells that can self-renew and generate tumor heterogeneity.Currently,endocrine resistance is a obstacle in endocrine therapy of patients with hormone receptor(HR)positive breast tumours.Existing studies provide evidence that BCSCs play an important role in endocrine therapy resistance in breast cancer.This article reviews the role of BCSCs in endocrine therapy resistance in HR+breast cancer.
作者
张浩
李玉凤
胡万宁
ZHANG Hao;LI Yufeng;HU Wanning(Graduate Institute of North China University of Science and Technology,Hebei Tangshan 063210,China;The Center Institute of Tangshan People's Hospital,Hebei Tangshan 063001,China;Tangshan Workers Hospital,Hebei Tangshan 063003,China)
出处
《现代肿瘤医学》
CAS
北大核心
2023年第19期3702-3706,共5页
Journal of Modern Oncology
基金
河北省分子肿瘤学重点实验室项目(编号:SZX2020043)。
关键词
激素受体阳性乳腺癌
内分泌治疗耐药
乳腺癌干细胞
hormone receptor positive breast cancer
endocrine therapy resistance
breast cancer stem cells
